香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 （於百慕達註冊成立之有限公司） （股份代號：621） 截至二零二五年三月三十一日止年度 全年業績公告 全年業績 Taung Gold International Limited（壇 金 礦 業 有 限 公 司*）（「本公司」）董 事 會（「董事會」） 欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 五 年 三 月 三 十 一 日 止 年 度 之 經 審 核 綜 合 全 年 業 績（連 同 截 至 二 零 二 四 年 三 月 三 十 一 日 止 年 度 之 比 較 數 字）如 下： 綜合損益及其他全面收益表 截至二零二五年三月三十一日止年度 | | | | | | | | | | | | | 二零二五年 | 二零二四年 | | --- | --- | --- | --- | --- | --- | --- | ...

Core Viewpoint - Netflix's forward P/E ratio has increased significantly from 15x in mid-2022 to 51x currently, indicating a substantial rise in market valuation despite competitive pressures from other streaming services like Warner Bros.' Max [1] Group 1 - In mid-2022, Netflix was trading at a forward P/E ratio of 15x [1] - The current forward P/E ratio for Netflix is 51x, reflecting a dramatic increase [1] - The competitive landscape includes other streaming services, notably Warner Bros.' Max, which may impact Netflix's market position [1]

久期财经讯，6月30日，上周iBoxx中资美元债投资级指数上涨0.59，投机级上涨1.25;iBoxx中资美元债投资级到期收益率下跌0.06%，投机级下跌0.12%。 国内宏观新闻方面，中国人民银行等六部门联合印发《关于金融支持提振和扩大消费的指导意见》，其中提到，夯实宏观经济基础，稳定消费预期。加大实 体经济支持力度，强化金融与财政、产业等政策协同联动。实施好货币政策，加强逆周期和跨周期调节，综合运用准备金、再贷款再贴现、公开市场操作等 多种货币政策工具，保持流动性充裕，持续推动社会综合融资成本下降。实施好财政政策，更好发挥消费在畅通国民经济循环、拉动经济增长中的积极作 用。健全投资和融资相协调的资本市场功能，推动中长期资金入市，促进资本市场稳定发展。 中国人民银行货币政策委员会2025年第二季度(总第109次)例会于6月23日召开。会议研究了下阶段货币政策主要思路，建议加大货币政策调控强度，提高货 币政策调控前瞻性、针对性、有效性，根据国内外经济金融形势和金融市场运行情况，灵活把握政策实施的力度和节奏。保持流动性充裕，引导金融机构加 大货币信贷投放力度，使社会融资规模、货币供应量增长同经济增长、价格总水平 ...

Core Viewpoint - A lawsuit has been filed against Reddit, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentations about user growth impacted by Google's AI technology [1][2][3]. Company Overview - Reddit operates a social news aggregation and forum platform, which has seen a decline in user traffic due to Google's AI search results providing answers directly, reducing the need for users to visit Reddit [3][4]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Northern District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. Stock Performance - Following a report on May 1, 2025, indicating a slowdown in daily active user growth, Reddit's stock price fell from $118.79 to $113.83, a decline of $4.96 or over 4% [5]. - On May 21, 2025, after an analyst cut the stock price target due to concerns over Google's AI impact, Reddit's stock dropped from $105.64 to $95.85, a decrease of $9.79 or over 9% [6].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant cut in dividends [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Allegations Against Hims & Hers - Hims & Hers operates a telehealth platform providing access to healthcare consultations and wellness products, and recently announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, specifically regarding the sale of Wegovy and compounded semaglutide, and claims of compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' alleged deceptive practices, Hims & Hers' stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Point - The Supervisory Board of Admirals Group AS has decided to recall Mr. Lauri Reinberg from the Management Board effective 26 June 2025 [1] Group 1 - Mr. Reinberg's authorizations will terminate on 25 June 2025 [1] - The Management Board will continue with members Alexander Tsikhilov, Eduard Kelvet, Anton Tikhomirov, and Andrey Koks effective 26 June 2025 [1] - Alexander Tsikhilov is the Chairman of the Management Board [1]

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shanyu Group Holdings Company Limited ⑂垓斄◖㉥佟㗇攎⊶ （於開曼群島註冊成立的有限公司） （股份代號：8245） 截至二零二五年三月三十一日止年度之年度業績 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在 聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公 司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買 賣之證券承受更大的市場波動風險，同時無法保證在GEM買賣的證券會有高 流通量的市場。 本公告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨 在提供有關善裕集團控股有限公司（「本公司」）的資料；本公司的董事（「董事」， 各自為一名「董事」）願就本公告的資料共同及個別地 ...